- Report
- April 2025
- 175 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- December 2024
- 30 Pages
Global
From €2911EUR$3,250USD£2,481GBP
From €4389EUR$4,900USD£3,741GBP
From €4389EUR$4,900USD£3,741GBP
- Report
- January 2025
- 175 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- April 2025
- 200 Pages
Global
From €7121EUR$7,950USD£6,070GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1791EUR$2,000USD£1,527GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €1791EUR$2,000USD£1,527GBP
- Report
- March 2025
- 114 Pages
Global
From €13431EUR$14,995USD£11,449GBP
- Report
- November 2022
- 230 Pages
Global
From €3359EUR$3,750USD£2,863GBP
- Report
- May 2024
- 136 Pages
Global
From €5821EUR$6,499USD£4,962GBP
- Report
- October 2023
- 145 Pages
Global
From €2821EUR$3,150USD£2,405GBP
- Report
- October 2023
- 145 Pages
Global
From €2821EUR$3,150USD£2,405GBP
- Report
- April 2023
- 240 Pages
Global
From €2911EUR$3,250USD£2,481GBP
- Report
- July 2022
- 196 Pages
Global
From €6718EUR$7,500USD£5,726GBP
- Report
- February 2022
- 269 Pages
Global
From €8509EUR$9,500USD£7,254GBP
- Drug Pipelines
- January 2022
- 100 Pages
Global
From €5105EUR$5,700USD£4,352GBP
- Report
- January 2024
- 143 Pages
Global
From €3807EUR$4,250USD£3,245GBP
- Report
- November 2022
- 107 Pages
Global
From €3538EUR$3,950USD£3,016GBP
- Report
- November 2022
- 175 Pages
Global
From €3224EUR$3,600USD£2,749GBP

Dupixent (dupilumab) is a biologic drug used to treat moderate-to-severe atopic dermatitis (eczema) in adults and adolescents aged 12 years and older. It is a monoclonal antibody that works by blocking two proteins, interleukin-4 (IL-4) and interleukin-13 (IL-13), which are involved in the inflammation and symptoms of atopic dermatitis. Dupixent is administered as an injection under the skin (subcutaneous) every two weeks.
The Dupixent market is a rapidly growing segment of the dermatological drugs market. It is a highly competitive market, with several companies offering similar products. Dupixent is the first biologic drug approved for the treatment of atopic dermatitis, and it has been shown to be effective in reducing symptoms and improving quality of life for patients.
Companies in the Dupixent market include Regeneron Pharmaceuticals, Sanofi, and AstraZeneca. Show Less Read more